4:41 PM
 | 
Dec 24, 2018
 |  BC Extra  |  Company News

AbbVie gets rights to Lupin's MALT1 program

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >